Several other equities analysts have also recently issued reports on the company. Baader Bank set a €22.00 ($26.19) price target on MediGene and gave the company a buy rating in a research report on Monday, April 16th. Oddo Bhf set a €13.00 ($15.48) price target on MediGene and gave the company a neutral rating in a research report on Friday, March 23rd.
MDG1 opened at €14.29 ($17.01) on Friday. MediGene has a one year low of €8.53 ($10.15) and a one year high of €19.27 ($22.94).
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.
Receive News & Ratings for MediGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene and related companies with MarketBeat.com's FREE daily email newsletter.